Bispecific antibody · Antagonist of Delta-like ligand 4 (DLL4) and Vascular endothelial growth factor A (VEGFA) · developed by Compass Therapeutics
Tovecimig is a bispecific antibody that simultaneously binds and blocks DLL4 and VEGF-A, preventing activation of DLL4/Notch and VEGF-A/VEGFR signaling pathways critical for angiogenesis and tumor vascularization. It is studied in biliary tract cancer, cholangiocarcinoma, gallbladder cancer, ampullary cancer, and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05506943 | Phase 2/3 | Biliary Tract Cancer | Active not recruiting | CMPS |
| NCT07662031 | Phase 2 | Colorectal Cancer | Not yet recruiting | CMPS |
| NCT04492033 | Phase 1/2 | P1b: Advanced Solid Tumors | Terminated | CMPS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ampullary CancerBiliary Tract CancerCholangiocarcinomaColorectal CancerGall Bladder CancerMetastatic Colorectal CancerP1b: Advanced Solid TumorsP2: Biliary Tract Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.
See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CMPS catalysts and pipeline →